Skip to main content
Premium Trial:

Request an Annual Quote

Shareholder Lawsuits Seek to Stop BGI's Buy of Complete Genomics

NEW YORK (GenomeWeb News) – Two lawsuits have been filed against Complete Genomics and BGI alleging a breach of fiduciary duties stemming from BGI's planned $117.6 million purchase of Complete Genomics.

One case, Budy Liauw v. Complete Genomics, was filed in the Superior Court for the State of California in the County of Santa Clara on Sept. 25. The other case, Irwin Hyman v. Complete Genomics, was filed in the Court of Chancery of the State of Delaware on Sept. 26. Both cases name the individual directors of Complete Genomics, as well as the company and BGI, as defendants.

The lawsuits claim that BGI's bid for Complete Genomics for $3.15 per share undervalues the company and shortchanges shareholders. In the meantime, "certain of the Company's named executive officers and board members will receive significant compensation in the form of severance payments and accelerated vesting of stock options and restricted stock – benefits that are not otherwise available to" shareholders, Liauw said in his complaint.

Both lawsuits seek class action status and ask the court for a preliminary and permanent injunction against completion of the deal.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.